中国中药杂志

2020, v.45(12) 2891-2902

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

基于构效差异的防治心肌缺血的三七皂苷亚组分表征分析技术
Characterization analysis technique of Panax notoginseng saponin subcomponents for prevention and treatment of myocardial ischemia based on their structure and effect differences

林传燕;杨冰;熊志伟;李畅;封亮;贾晓斌;
LIN Chuan-yan;YANG Bing;XIONG Zhi-wei;LI Chang;FENG Liang;JIA Xiao-bin;the Third Clinical Medical College, Nanjing University of Chinese Medicine;School of Traditional Chinese Medicine, China Pharmaceutical University;

摘要(Abstract):

依据三七皂苷组分(Panax notoginseng saponin components, PNSC)结构和效应差异进行亚组分划分和网络药理学药效表征,为三七皂苷亚组分成药性及单元制剂技术设计提供研究基础。通过TCMSP数据库筛选PNSC,并依据系统聚类划分亚组分。通过PharmMapper服务器,GeneCards,DisGeNET与HOME-NCBI-GENE数据库进行靶标预测和归属分析;采用STRING数据库绘制各亚组分靶标相互作用网络;采用DAVID数据库对各亚组分靶标进行KEGG和GO富集分析,采用Cytoscape软件构建亚组分-靶标-通路可视化网络,对亚组分靶标及涉及的通路进行对比,分析其抗心肌缺血药效机制的差异和亚组分划分的合理性。筛选得到18个三七皂苷化合物,根据其性质差异,划分出3个三七皂苷亚组分A,B,C,涉及67个作用靶标和17条与心肌缺血直接或间接相关的各亚组分共有通路。亚组分A涉及的靶标最多且相互作用密集,可能表明其在药效机制中的关键作用。亚组分A,B,C基本结构相似,KEGG和GO分析结果显示三七皂苷亚组分均可能通过抑制细胞凋亡、调节炎症反应和促进血管新生等过程,增强心脏功能和对心肌细胞的保护作用,从而发挥抗心肌缺血的作用。该研究充分体现出三七皂苷亚组分因结构性质的差异所导致的各亚组分在防治心肌缺血药效上的差异性,而各亚组分防治心肌缺血药效的差异也从一定程度上印证出三七皂苷亚组分依据结构性质划分的合理性,实现基于构效差异的三七皂苷亚组分性质的表征。
According to the structure and effect differences of Panax notoginseng saponin components(PNSC), subcomponent division and network pharmacological characterization were conducted to provide a research basis for the medicinal properties of P.notoginseng saponin subcomponents and the technical design of unit preparations. PNSC were screened by the TCMSP database and subcomponents were classified according to systematic clustering. Then the subcomponents obtained were subjected to target prediction and attribution analysis by PharmMapper server, GeneCards, DisGeNET and HOME-NCBI-GENE database. A subcomponent target interaction network was constructed by using the STRING database. KEGG and GO enrichment analysis were performed on each subcomponent target using the DAVID database. The subcomponents-targets-pathways visualization network was constructed by Cytoscape. The subcomponent targets and pathways involved were compared to analyze the differences in anti-myocardial ischemic drug mechanisms and the rationality of subcomponent division. Eighteen compounds of PNSC were screened out, and classified into three subcomponents A, B, and C according to their properties, involving 67 targets and 17 common anti-myocardial ischemic pathways directly or indirectly related to myocardial ischemia. Subcomponent A had the highest number of targets and the target interaction was dense, possibly indicating its key role in the mechanism of pharmacodynamics. Subcomponents A, B, and C had similar basic structures, and KEGG and GO analysis showed that they all can enhance the heart function and protection of cardiomyocytes by inhibiting apoptosis, promoting angiogenesis and regulating inflammatory response to play the effect on myocardial ischemia. This study fully reflected the differences in the efficacy of various subcomponents in preventing and treating myocardial ischemia due to the different physical properties of P. notoginseng saponin subcomponents. To some extent, the differences in the efficacy of each subcomponent in the prevention and treatment of myocardial ischemia could verify the rationality of the division of P. notoginseng saponin subcomponents according to the structural properties, realizing the characterization of P. notoginseng saponin subcomponents based on structure and effect differences.

关键词(KeyWords): 三七皂苷组分;构效差异;亚组分划分;亚组分表征分析技术;心肌缺血;网络药理学
Panax notoginseng saponin components;structure and effect difference;subcomponent division;subcomponent characterization analysis technique;myocardial ischemia;network pharmacology

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金项目(81573620);; 国家重点研发计划项目(2018YFC1706900);; 中国药科大学双一流项目(CPU2018GF07,CPU2018PZQ19)

作者(Author): 林传燕;杨冰;熊志伟;李畅;封亮;贾晓斌;
LIN Chuan-yan;YANG Bing;XIONG Zhi-wei;LI Chang;FENG Liang;JIA Xiao-bin;the Third Clinical Medical College, Nanjing University of Chinese Medicine;School of Traditional Chinese Medicine, China Pharmaceutical University;

Email:

DOI:

参考文献(References):

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享